
Treatment GuideJust DiagnosedSex & DatingAfrican AmericanStigmaAsk the HIV DocPrEP En EspañolNewsVoicesPrint IssueVideoOut 100
CONTACTCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2025 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Privacy Policy and Terms of Use.
At one of the last major AIDS conferences of 2008 (the Interscience Conference on Antimicrobial Agents and Chemotherapy) researchers indicated that the end for what many have characterized as a dry spell in anti-HIV drug development may finally be on the horizon, with promising data on three new medications. ''Bevirimat. Although researchers had struggled with liquid versus tablet formulations of this maturation inhibitor and initially had difficulty achieving formulations with therapeutic drug levels, the kinks were finally worked out and data from a Phase II human trial were presented. They showed that bevirimat lowered viral loads by a 1.2-log drop after just two weeks of treatment. And more good news: Reported side effects were the same as those associated with use of a placebo. Final Phase III clinical trials are coming. ''Elvucitabine. This new nucleoside analog is similar to Epivir (3TC) but has demonstrated activity against HIV that has developed a major genetic mutation conveying resistance to 3TC. Elvucitabine appears to be more potent than 3TC in treating hepatitis B as well. A small study comparing elvucitabine and 3TC in combination with Viread and Sustiva showed that the new medication performed slightly less well, but researchers say that was likely due to the unexplained dropout of some participants in the elvucitabine arm. Side effects were not the cause. Studies are ongoing. ''RDEA-806. Although researchers are still grappling with formulation problems with this new nonnucleoside reverse transcriptase inhibitors, the medication has been shown to be effective against HIV with K103N mutations that convey resistance to most other nonnuke meds. Data from a Phase IIa trial showed that RDEA-806 produced a 1.8-log drop in viral levels after seven days of treatment, and there were no reports of the central nervous system side effects or rash linked with other NNRTIs. The developers say they believe it may take multiple viral genetic mutations for HIV to develop resistance against RDEA-806. Phase IIb clinical trials are about to start. Researchers at the conference also presented data from the North American AIDS Cohort Collaboration on Research and Design study, which showed that delaying the initiation of HIV treatment until CD4-cell counts were below 350 worsened morbidity and mortality statistics. Earlier initiation of anti-HIV therapy should provide for better rises in CD4-cell counts, more successful viral suppression, and a reduced risk of cardiac, liver, and renal disease as well as non-HIV related cancer, according to the study. U.S. and U.K. treatment guidelines as well as those of the International AIDS Society already call for the initiation of antiretroviral therapy when CD4-cell counts are above 350 on a case-by-case basis. In my next column I'll discuss more reports from the conference, including some impressive studies that used the latest technology to explore the possibility of eradicating HIV reservoirs and the release of data on new, highly sensitive resistance assays. Stay tuned for what is shaping up to be a good year for treatment. Bowers is an HIV specialist and is board-certified in family medicine. He is in private practice in New York City. Learn more about Bowers at https://www.danbowersmd.com
From our Sponsors
Most Popular
Lexi Love comes out as HIV+ after Trump deletes federal resources
January 23 2025 11:23 AM
Grindr is reminding us why jockstraps are so sexy and iconic
May 02 2025 5:36 PM
BREAKING NEWS: Trump admin moves to end federal HIV prevention programs
March 18 2025 6:10 PM
Trump's orders prompt CDC to erase HIV resources
January 31 2025 5:29 PM
This long-term HIV survivor says testosterone therapy helped save his life.
December 16 2024 8:00 PM
Celebrating Black History Month with our annual African American issue
February 01 2025 3:28 PM
Discover the power of Wellness in your life
March 26 2025 12:41 PM
Tyler TerMeer vows to continue to fight for health care for all
January 28 2025 3:00 PM
Plus: Featured Video
Latest Stories
Trump admin guts $258 million in funding for HIV vaccine research
June 03 2025 3:47 PM
HRC holds 'die-in' to protest Trump health care cuts
April 28 2025 2:11 PM
Two right-wing Supreme Court justices signal they may uphold access to PrEP and more
April 21 2025 4:10 PM
500,000 Children at Risk: PEPFAR Funding Crisis
April 08 2025 3:51 PM
Broadway's best raise over $1 million for LGBTQ+ and HIV causes
April 03 2025 7:15 PM
The Talk Season 5 premieres this spring with HIV guidance for the newly diagnosed
March 26 2025 1:00 PM
Season 4 of The Switch on resilience & radical self-love returns this spring
March 26 2025 12:20 PM
Jess King is here to help you live your happiest, healthiest life yet
March 24 2025 4:35 PM
Gerald Garth is keeping people of color happy and healthy through trying times
March 11 2025 3:38 PM
Plus nominated for 2025 GLAAD Media Award
January 22 2025 12:42 PM
A camp for HIV-positive kids is for sale. Here's why its founder is celebrating
January 02 2025 12:21 PM
'RuPaul's Drag Race' star Trinity K Bonet quietly comes out trans
December 15 2024 6:27 PM
Ricky Martin delivers showstopping performance for 2024 World AIDS Day
December 05 2024 12:08 PM
AIDS Memorial Quilt displayed at White House for the first time
December 02 2024 1:21 PM
Decades of progress, uniting to fight HIV/AIDS
December 01 2024 12:30 PM
Hollywood must do better on HIV representation
December 01 2024 9:00 AM
Climate change is disrupting access to HIV treatment
November 25 2024 11:05 AM
California confirms first case of even more deadly mpox strain
November 18 2024 3:02 PM